Stockscreener 앱 받기
0.7959
0.25%
-0.0002
시간 외 거래:
.80
0.0041
+0.52%
전일 마감가:
$0.7961
열려 있는:
$0.81
하루 거래량:
468.41K
Relative Volume:
0.52
시가총액:
$89.45M
수익:
$3.17M
순이익/손실:
$-36.23M
주가수익비율:
-1.9469
EPS:
-0.4088
순현금흐름:
$-17.11M
1주 성능:
+2.21%
1개월 성능:
+13.88%
6개월 성능:
-37.96%
1년 성능:
+44.38%
1일 변동 폭
$0.7751
$0.816
1주일 범위
$0.7701
$0.8238
52주 변동 폭
$0.4404
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
명칭
Rani Therapeutics Holdings Inc
전화
(408) 457-3700
주소
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7959 | 89.47M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-06-14 | 개시 | Maxim Group | Buy |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-07-27 | 개시 | H.C. Wainwright | Buy |
| 2022-06-13 | 개시 | Wedbush | Outperform |
모두보기
Rani Therapeutics Holdings Inc 주식(RANI)의 최신 뉴스
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - GlobeNewswire
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
IMDX Stock Price and Chart — NASDAQ:IMDX - TradingView
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics appoints Michelle Gilson to board - Investing.com
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Rani Therapeutics appoints Michelle Gilson to board and as Audit Committee chair - TradingView
Rani Therapeutics Appoints Michelle Gilson to Board of Directors - Yahoo Finance
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Enterprise value to EBITDA forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - tradingview.com
Vanguard Capital Management discloses 5,052,862 Rani Therapeutics (RANI) shares in ownership report - Stock Titan
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Insider Buying: Rani Therapeutics (NASDAQ:RANI) Director Buys $24,840.00 in Stock - MarketBeat
Rani Therapeutics Holdings Inc (RANI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.810|Chg%:-0.000 - TradingKey
Rani Therapeutics Holdings Inc (RANI) Institutional Confidence - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.805|Chg%:+0.007 - TradingKey
Rani Therapeutics Hldgs Market Sentiment - Benzinga España
RANI|Rani Therapeutics Holdings Inc|Price:0.801|Chg%:-0.009 - TradingKey
TradingKey - TradingKey
Rani Therapeutics Holdings Inc (RANI) Cash Flow - TradingKey
Rani Therapeutics Holdings Inc (RANI) Balance Sheet - TradingKey
Rani Therapeutics director Mir A Imran buys $24,839 in stock - Investing.com UK
Form 4 Rani Therapeutics Holdings Inc For: 24 July By Investing.com - Investing.com South Africa
Rani Therapeutics director Mir A Imran buys $24,839 in stock By Investing.com - Investing.com Nigeria
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics (RANI) insider Imran Mir A buys 36,000 shares - Stock Titan
Rani Therapeutics Holdings (NASDAQ:RANI) surges 29%, shrinking Nasdaq compliance deficit to 11% - TechStock²
Rani Therapeutics Holdings Inc (RANI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rani Therapeutics Holdings Inc 주식 (RANI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Javadi Alireza | Chief Technical Officer |
Mar 27 '26 |
Sale |
0.78 |
386 |
301 |
9,689 |
| Imran Talat | Chief Executive Officer |
Jul 17 '26 |
Buy |
0.72 |
35,000 |
25,193 |
469,736 |
| IMRAN MIR A | Director |
Oct 23 '25 |
Buy |
0.60 |
2,083,334 |
1,260,417 |
2,083,334 |
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.67%
0.04%
자본화:
|
볼륨(24시간):